HIV and STI epidemiology in high-risk populations in the Netherlands
van Veen, M.G.

Citation for published version (APA):
van Veen, M. G. (2010). HIV and STI epidemiology in high-risk populations in the Netherlands

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Increasing trend in gonococcal resistance to ciprofloxacin in The Netherlands, 2006–8

F D H Koedijk, M G van Veen, A J de Neeling, G B Linde, M A B van der Sande

ABSTRACT

Introduction Rapid development of N. gonorrhoeae resistance to several antibiotics in recent years threatens treatment and prevention. Targeted surveillance of new resistance patterns and insight into networks and determinants are essential to control this trend.

Methods Since the Gonococcal Resistance to Antimicrobials Surveillance (GRAS) project was implemented within the Dutch national sexually transmitted infection (STI) surveillance network in July 2006, participating STI centres have collected a culture from each gonorrhoea patient. Isolates were tested for susceptibility to penicillin, tetracycline, ciprofloxacin and ceftriaxone using Etest. Logistic regression was used to determine risk factors for ciprofloxacin resistance.

Results Between July 2006 and July 2008, prevalence of resistance to penicillin was 10% to tetracycline 22% and to ciprofloxacin 42%. Resistance to ceftriaxone was not found, although minimum inhibitory concentrations higher than 0.125 mg/l drifted upward (p < 0.05).

Ciprofloxacin resistance rose from 35% in 2006 to 46% in 2008 (p < 0.05), despite 2003 guidelines naming ceftriaxone the first-choice therapy. In men, ciprofloxacin resistance was higher in men having sex with men (HIV-positive) than in heterosexual men (adjusted OR 2.0, 95% CI: 1.5 to 2.6). In women, it was higher in commercial sex workers (adjusted OR 25.0, 95% CI: 7.7 to 78.2) and women aged over 35 years (adjusted OR 8.2, 95% CI: 3.0 to 22.7) than in other women.

Conclusion Ciprofloxacin resistance in The Netherlands is increasing, and is in particular found in MSM, older women, and female sex workers. No resistance to current first-choice therapy was found, but awareness to potential clinical failures is essential. By merging epidemiological and microbiological data in GRAS, specific high-risk transmission groups can be identified and policy adjusted when needed.

Gonorrhoea is the second most common bacterial sexually transmitted infection (STI) in The Netherlands. Under the national sentinel surveillance programme in STI centres, 1127 cases were reported in 2007. Approximately 69% of the male cases were diagnosed among men who have sex with men (MSM), with a positivity rate of 8.9%. In heterosexual men and women, the positivity rate was 1.5% and 1.1%, respectively. In 2007, 14% of the new cases of gonorrhoea diagnosed were in people known to have an HIV infection, and 2% were simultaneously diagnosed with an HIV infection and gonorrhoea. An infection with gonorrhoea increases the risk of acquiring HIV infection and may increase the viral load in those already HIV infected. Infection with N. gonorrhoeae in men and women is an important cause of epididymitis, cervicitis, urethritis and pelvic inflammatory disease. Pelvic inflammatory disease may further lead to ectopic pregnancy, infertility or abortion.

Rapid and appropriate treatment of gonorrhoea is of great importance for public health, because it shortens the infectious period and limits transmission of the disease. The World Health Organisation recommends that first-choice therapy for gonorrhoea needs to cure at least 98% of those infected.

National surveillance of antimicrobial resistance in gonorrhoea was conducted in The Netherlands from 1976 until 1999, the period in which reporting the disease was mandatory. Since then, national insight into its incidence, and also into resistance patterns of gonorrhoea, has been lacking, despite signs of increases in gonorrhoea infections and in resistance to fluoroquinolones such as ciprofloxacin.

Initially, penicillin was the primary therapy for gonorrhoea in The Netherlands. In 1997, the spread of penicillin-resistant N. gonorrhoea led to modification of the guidelines towards single-dose therapy with ciprofloxacin or ceftriaxone. Indications of increasing quinolone resistance resulted in another revision of the guidelines in 2005, making ceftriaxone the first-choice therapy for gonorrhoea infections. At the end of 2006, ceftriaxone was selected as the primary therapy.

Results from an annual nationwide laboratory surveillance questionnaire, administered since 2002, showed a remarkable increase in resistance to quinolones from 6.9% in 2002 to 26.4% in 2005. The questionnaire did not collect any epidemiological or clinical information on gonorrhoea patients. As this is essential to ensure adequate and appropriate treatment and prevention guidelines, the project Gonococcal Resistance to Antimicrobials Surveillance (GRAS) was initiated in 2006. Here, we analyse and discuss methods and results of the first 2 years of GRAS, with a focus on the determinants of resistance to ciprofloxacin (previous first-choice therapy) and third generation cephalosporins (current first-choice therapy).

METHODS

GRAS is implemented within the present Dutch national STI surveillance network, in which 32 STI centres and laboratories across eight regions provide free STI testing and care to people in specific high-risk groups, including those who wish to be tested anonymously. This system of testing and care was set up in addition to the routine national health services, to reach people who might otherwise not be
susceptibility testing

From July 2006 until July 2008, all participating STI centres collected a sample for culture and susceptibility testing from each gonorrhoea patient. In July 2006, GRAS was implemented in its first participating STI centre. Throughout the years 2006 to 2008, the project was implemented further, and as of June 2008, it included 15 of the Dutch STI centres, representing 85% of the total population of clinic attendees. Three STI centres stopped participating in 2007 for logistic or financial reasons.

The antimicrobial susceptibility of gonococcal isolates was tested locally at the laboratories related to the STI centres; each isolate was tested for its susceptibility to penicillin, tetracycline, ciprofloxacin and ceftaxime (as this was first-choice therapy when implementing GRAS in June 2008) using Etest (AB Biodisk, Solna, Sweden). Minimum inhibitory concentration (MIC) breakpoints were 2 mg/l or greater for penicillin, 1 mg/l or greater for ciprofloxacin, 2 mg/l or greater for tetracycline and over 0.5 mg/l for ceftaxime, according to guidelines recommended by the Clinical and Laboratory Standards Institute.

To enable comparability of the microbiological data, a quality control system was developed for GRAS, based on the standards for quality control in surveillance of antibiotic resistance that were devised by the Dutch Foundation of the Working Party on Antimicrobial Policy. At the beginning of participation in GRAS, the laboratories tested a panel of four control strains (including N gonorrhoeae ATCC49226 and these strains kindly provided by C. Giu). Each laboratory was allowed to use its own methods, including the agar medium, but had to identify the MIC of each antibiotic for the four reference strains. The MIC of the ATCC reference strain had to be within the boundaries prescribed by the Clinical and Laboratory Standards Institute.

Data collection and analysis

For routine national surveillance, new STI consultations and corresponding diagnoses were reported to the Dutch Centre for Infectious Disease Control, facilitated by a web-based application (SOAP). An anonymous report is submitted for each visitor, containing epidemiological, clinical data and test results on a wide range of STI. For GRAS, MIC values were collected for each patient diagnosed with gonorrhoea and reported to SOA.

The χ² test was used to assess the significance of differences among groups. Time trends in antimicrobial resistance were assessed by using the χ² test for trends. Associations between ciprofloxacin-resistant and ciprofloxacin-susceptible patients were analysed using logistic regression models. Multivariate analysis was performed by using all variables with clinical and statistical importance (p<0.05), estimated by gender. All statistical analyses were performed using SPSS software, version 15.0.

RESULTS

Between July 2006 and July 2008, susceptibility testing for N gonorrhoeae was performed for isolates from 1556 patients (774 in 2006, 1105 in 2007 and 443 in the first half of 2008), covering 66% of all patients (n=2377) diagnosed in the participating STI centres (since they started or till they stopped participating). No laboratory were excluded as comparable results were achieved for the quality control, the mean log (MIC) of the four reference strains of any laboratory did not differ more than 1.5 from the overall mean log (MIC) of each antibiotic.

Most of the patients with an isolate were men (87%), of whom 78% were MSM (Table 1); 61% of the cases were people of Dutch origin and 21% were HIV positive (before or simultaneous with their gonorrhoea diagnosis). Patients with an isolate differed significantly from patients without an isolate, according to most of the main characteristics (Table 1). Patients with an isolate were more often men, older, from the western part of The Netherlands, non-Dutch, MSM and HIV positive. No significant trends in time in patient characteristics were found, except for HIV status and region.

The results show a prevalence of resistance to ciprofloxacin of 42% (increasing significantly from 35% in 2006 to 46% in 2008, p<0.05), to tetracycline of 22% (changing over time from 22% in 2006 to 27% in 2008, p<0.05) and to penicillin of 10% (decreasing over time from 10% in 2006 to 7% in 2008, p<0.05). Resistance to cefotaxime was not found.

Of all tested isolates, 99% (n=600) were resistant to one of the antimicrobial drugs tested, 14% (n=220) to two and 3% (n=39) to three of the antimicrobial agents tested; 45% (n=697) were susceptible to all antimicrobial drugs tested.

Ciprofloxacin resistance

N gonorrhoeae infection with ciprofloxacin-resistant bacteria increased from 35% in 2006 to 46% in 2008 (p<0.05, Figure 1). Univariate analyses showed that the risk of an infection with ciprofloxacin-resistant gonorrhoea increased significantly over time in men (Table 1). It was also found that isolates from men

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients with an isolate (n=1374)</th>
<th>Patients without an isolate (n=987)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1349 (99.7)</td>
<td>1339 (87.7)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Female</td>
<td>25 (1.2)</td>
<td>98 (6.1)</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>&lt;35</td>
<td>454 (33.1)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Age, years</td>
<td>≥35</td>
<td>801 (60.5)</td>
<td></td>
</tr>
<tr>
<td>Region</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>North</td>
<td>7 (0.5)</td>
<td>22 (2.2)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>South</td>
<td>81 (6.0)</td>
<td>173 (17.4)</td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>1853 (69.4)</td>
<td>487 (49.0)</td>
<td></td>
</tr>
<tr>
<td>East</td>
<td>15 (1.0)</td>
<td>20 (2.0)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dutch</td>
<td>639 (45.1)</td>
<td>543 (54.1)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Non-Dutch</td>
<td>695 (49.4)</td>
<td>444 (44.9)</td>
<td></td>
</tr>
<tr>
<td>Sexual preference in men</td>
<td>No</td>
<td>801 (60.2)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>573 (42.1)</td>
<td></td>
</tr>
<tr>
<td>HIV status and region</td>
<td>No</td>
<td>987 (72.5)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>20 (2.0)</td>
<td></td>
</tr>
<tr>
<td>History of STD</td>
<td>No</td>
<td>176 (13.0)</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>404 (29.9)</td>
<td></td>
</tr>
</tbody>
</table>

Table 1 Characteristics of gonorrhoea patients with and without an isolate for susceptibility testing, The Netherlands, July 2006–July 2008
Aged over 35 years were more likely to be resistant to ciprofloxacin than those from younger men (odds ratio (OR) 1.6, table 2). Furthermore, ciprofloxacin resistance was significantly higher in MSM than in heterosexual men (OR 2.0). Infection with N. gonorrhoeae resistant to ciprofloxacin was more likely in Dutch than non-Dutch men (OR 1.6) and in HIV-positive men than in HIV-negative men (OR 1.5). Being a client of a commercial sex worker (CSW), urbanisation and region were no significant risk factors. Five variables were significant in the univariate regression analyses and were included in the final multivariate logistic regression model for men (table 2). When adjusted for all these factors, only MSM and year of consultation were found to be associated with ciprofloxacin resistance in men (adjusted OR 2.0 for MSM and 1.5 and 1.6 for 2007 and 2008, respectively). As with men, ciprofloxacin resistance was higher in women older than 35 years (OR 6.0, table 2). Furthermore, women who reported commercial sex contacts in the past 6 months were more likely to be resistant to ciprofloxacin than women who did not (OR 25.2). Dutch women were less likely than non-Dutch women to be infected with N. gonorrhoeae resistant to ciprofloxacin (OR 0.6, but not significantly). When these three variables were tested in a multivariate model, age above 35 years and commercial sex work remained significant risk factors for resistance to ciprofloxacin in women (adjusted OR 0.2 and 25.5, respectively).

Cephalosporin resistance

No resistance to cefuroxime was found. The distribution of MIC values for cefotaxime showed a slight upward drift between 2006 and 2008 (figure 2), as the proportion of isolates with an MIC value higher than 0.125 mg/l increased significantly in that period (p<0.05). An MIC value of 0.38 mg/l was found in seven isolates, of which five were from MSM.

**DISCUSSION**

The prevalence of N. gonorrhoeae resistant to ciprofloxacin has increased to 40% in 2005, despite a 2003 revision of the guidelines mandating its replacement by third-generation cephalosporins. Whereas resistance to cefuroxime was not found, an upward drift among its MIC values was observed during the study period. These findings suggest that in the future, novel (multi-drug) treatment options might be needed to treat N. gonorrhoeae effectively, to prevent an upsurge of gonorrhoea infections.

Antimicrobial resistance in N. gonorrhoeae is a growing worldwide public health problem. Increasing trends in ciprofloxacin resistance have been observed in most European countries, as well as in other countries worldwide.10–13 In the Netherlands, the prevalence of ciprofloxacin resistance increased significantly over time in men and was found to be significantly higher in MSM than in heterosexual men, whereas in women, CSW and women aged above 35 years were most likely to have an infection with ciprofloxacin-resistant bacteria. Current findings show that risk-group patterns of resistance to the newer antibiotics echo patterns seen when penicillin resistance emerged in The Netherlands in the 1980s. Pencillin-resistant
resistance was mainly associated with transmission in high-risk individuals such as CSW and MSM, and these high-risk groups are now most likely to acquire an infection caused by ciprofloxacin-resistant bacteria, according to reports published worldwide. Insight into resistance patterns in diverse sexual networks may add to our understanding of the transmission dynamics of gonorrhoea in those populations. The presence of distinct heterosexual and homosexual networks, each showing sustained transmission, may explain the ongoing increase in the prevalence of ciprofloxacin resistance despite its decreased use in STI centres in The Netherlands. The guidelines of the National Society for Venereology and Dermatology were changed in 2005 and recommend that ciprofloxacin be replaced by third-generation cephalosporins, as in many other countries. However, outside STI centres in The Netherlands ciprofloxacin may still be prescribed for N. gonorrhoeae, especially since general practitioners (GPs) still mention ciprofloxacin as the second choice of therapy in 2009 (guidelines will be updated in 2009).

All isolates we tested were susceptible to cefotaxime, and no failures in its treatment of gonorrhoea have yet been reported in The Netherlands. However, we observed an upward shift in its MIC values reported by GRAS participants. Isolates showing reduced susceptibility (MIC value 0.19 mg/l) to cefotaxime and ceftriaxone have been reported since before 2006 in Asia and Australia and also recently in Europe, although therapeutic failures have not been reported. Therefore, monitoring the susceptibility to cefotaxime is of high importance.

These first results from the GRAS project should nevertheless be interpreted with caution. The characteristics of patients from whom bacteria were isolated or not differed significantly for some variables, and susceptibility testing was performed in only 66% of all gonorrhoea patients diagnosed at the participating STI centres in the study period. Moreover, an important obstacle to obtaining samples for susceptibility testing is the need to store and transport them rapidly and appropriately to a laboratory for culturing. All STI centres participating in GRAS were instructed to grow cultures for susceptibility testing, but specimen collection and transport failed on some occasions. Also, some of the samples had a positive PCR test and negative culture results representing a false-positive PCR. Finally, some STI centres asked for a culture only when an asymptomatic patient reported back for treatment due to a positive PCR, and some of these patients may have spontaneously recovered from the infection or obtained treatment elsewhere. At the moment, research is ongoing to evaluate the possibility of using molecular techniques (PCR) to monitor resistance patterns, in order to circumvent the cumbersome transport and storage procedures needed to enable culturing.

Another limitation of GRAS is its focus on high-risk patients attending STI centres rather than numbers of the general public visiting their GP. In The Netherlands, there is currently no systematic collection of data on the susceptibility patterns of gonorrhoea patients diagnosed by GPs (or by other healthcare professionals outside the STI centre system), although approximately 70% of all STI in The Netherlands are diagnosed by GPs. Unlike Chlamydia, however, transmission of N. gonorrhoeae appears to occur predominantly among high-risk groups. Therefore, targeted surveillance of N. gonorrhoeae resistance among high-risk transmitters, as monitored by GRAS, is important for the early detection of changing resistance patterns as this may necessitate the modification of treatment guidelines. Targeted surveillance also enables the exploration of risk factors for infection with such strains and the understanding of high-risk transmission patterns. Development of resistance in the wider community is associated with the importation of new strains and their spread in the community following initial transmission in high-risk groups. Indeed, these high-risk groups are the groups visiting STI centres.

In conclusion, by merging epidemiological data with data on antimicrobial resistance in GRAS, we identified specific risk groups, enabling adjusted treatment guidelines for those groups. Our results show that the prevalence of ciprofloxacin resistance in The Netherlands is still increasing and is particularly high in MSAs, older women and female CSW. Resistance to the current first-choice therapy has not yet been found. However, monitoring and clinical awareness is essential, as the MIC values of cefotaxime are increasing.

**Key messages**

- Ciprofloxacin resistance is still increasing in The Netherlands.
- No resistance to current first-choice therapy has been found yet; however, monitoring is essential.
- By merging epidemiology with microbiology in GRAS, risk groups for antimicrobial resistance can be identified and treatment guidelines can be adjusted when needed.
ACKNOWLEDGEMENTS

The authors thank all STI centres and medical microbiology laboratories in The Netherlands for their contribution in data collection. A van Deurijn (Amsterdam), B van der Heijden (Diemen), S van der Goor (Rotterdam), and R Ubbink (Utrecht) for their contribution in laboratory work. T de Jonge (The Hague), N van den Broek (Amsterdam), and G van der Stee (Amsterdam) for their contribution in laboratory work. M van Santen-Verheuvel, R van Veen, H van den Brink, J Spaargaren, and P van Voorst Vader (The Hague) for their contribution in laboratory work.

REFERENCES


